TRIMURTHI
GROUP

Date: 10.02.2020

To,
The Secretary,
The B.S.E Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai – 400 001

Sub: Submission of Un-Audited Standalone Financials Results of the Company and Limited Review Report as per Provisions of Regulation 30, 33 of SEBI (LODR) Regulations, 2015.

Please find enclosed here with the following Documents in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015:

1. Financial Results: Un-Audited Standalone & Consolidated Financial Results of the company for the Third Quarter Ended 31st December, 2019.

2. Limited Review Report: A Certified Copy of the Limited Review Report on Standalone Financials for the Third Quarter Ended 31st December, 2019 by the Auditors.

This is for your Information and Necessary Records.

Thanking you
For **TRIMURTHI LIMITED**

TRIMURTHI LIMITED HYDERABAD

Arun Kumar Bhangadia
Managing Director
DIN: 00021024

TRIMURTHI LIMITED
(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

TRIMURTHI
GROUP

Date: 10/02/2020

To,
The Secretary,
The B.S.E Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai- 400 001

Sub: Outcome of the Board Meeting held on 10/02/2020 as per Regulation 30, 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held today, Monday, the 10th Day of February, 2020 at Registered Office, have approved and taken on record the following:

1. The Board has considered and approved the minutes of the previous board meeting.

2. The Board has considered and approved the Unaudited Standalone & Consolidated Financial Results for the Third Quarter ended 31st December, 2019 along with Limited Review Report issued by the Statutory Auditors of the Company in compliance with Indian Accounting Standards (Ind-AS), SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.

There being no other matter meeting of the Board of Directors concluded with the vote of thanks.

The Meeting of the Board of Directors of the company commenced at 03.30 P.M. and Concluded at 04:30 P.M.

Request you to take same on records.

Thanking you
For **TRIMURTHI LIMITED**

TRIMURTHI LIMITED HYDERABAD

Arun Kumar Bhangadia
Managing Director
DIN: 00021024

TRIMURTHI LIMITED
(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED
4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095.
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS
FOR THE QUARTER ENDED DECEMBER 2019

Rs. in lakhs except share data

PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
	31.12.2019 (UNAUDITED)	30.09.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.03.2019 (AUDITED)
1. INCOME						
INCOME FROM OPERATIONS	18.34	14.73	98.89	52.20	310.36	359.19
OTHER INCOME	11.90	8.26	(0.31)	36.90	2.10	13.23
TOTAL INCOME	30.24	23.00	98.57	89.10	312.45	372.43
2. EXPENSES						
PURCHASES	12.94	18.37	89.56	48.41	250.31	277.05
COST OF MATERIALS CONSUMED		-			-	-
MANUFACTURING EXPENSES		-			-	-
WORK IN PROGRESS AND STOCK IN TRADE	3.91	1.52	(7.30)	3.57	(0.14)	0.03
RENT	0.30	0.60	1.00	0.90	2.25	3.00
EMPLOYEE BENEFITS EXPENSE	8.57	7.35	9.95	21.40	24.65	32.72
FINANCE COSTS	-	-		-		-
DEPRECIATION AND AMORTISATION EXPENSES	2.26	1.97	2.80	6.90	8.81	12.15
OTHER EXPENSES	3.69	4.55	2.17	16.91	21.69	28.39
TOTAL EXPENSES	31.67	34.36	98.18	98.10	307.58	355.34
3. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE EXCEPTIONAL ITEMS (1-2)	(1.42)	(11.36)	0.39	(9.00)	4.88	19.08
4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS					-	
PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (3	(1.42)	(11.36)	0.39	(9.00)	4.88	19.08
6. TAX EXPENSES	0.01	(1.02)	(4.74)	0.06	(9.44)	(54.92)
-CURRENT TAX	-	(1.10)	0.70	-	0.70	4.49
-TAX ADJUSTMENTS RELATING TO EARLIER YEARS		-				
-DEFERRED TAX (NET)	0.01	0.08	(5.44)	0.06	(10.14)	(10.04)
7. NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (5-6)	(1.43)	(10.34)	5.13	(9.06)	14.31	25.00
8.PROFIT /(LOSS) FROM DISCONTINUED OPERATIONS						
9.TAX EXPENSES FOR DISCONTINUED OPERATIONS						
10.PROFIT /(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9)						
11.PROFIT/(LOSS) FOR THE PERIOD (7+10)	(1.43)	(10.34)	5.13	(9.06)	14.31	25.00
12.OTHER COMPREHENSIVE INCOME						
LOSS (ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS	(0.19)	0.67	(2.30)	(1.42)	(10.12)	(6.20)
B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS (ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS						
13.TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME)	(1.62)	(9.67)	2.82	(10.49)	4.19	18.80
14.EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION) :						
(i) BASIC	(0.02)	(0.13)	0.06	(0.11)	0.18	0.31
(ii) DILUTED	(0.02)	(0.13)	0.06	(0.11)	0.18	0.31
15.EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION) :						
(i) BASIC						
(ii) DILUTED						
16.EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION) :						
(i) BASIC	(0.02)	(0.13)	0.06	(0.09)	0.18	0.31
(ii) DILUTED	(0.02)	(0.13)	0.06	(0.09)	0.18	0.31

TRIMURTHI LIMITED HYDERABAD

Arun Kumar

TRIMURTHI LIMITED
(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED
SCHEDULE III OF THE COMPANIES ACT 2013
PART-II

	PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2019 (UNAUDITED)	30.09.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.03.2019 (AUDITED)
A.	PARTICULARS OF SHARE HOLDING						
1.	Public Share Holding						
	- Number of Shares	29,00,600	29,00,600	29,00,600	29,00,600	29,00,600	29,00,600
	- Percentage of shareholding	35.81%	35.18%	35.81%	35.81%	35.81%	35.81%
2.	Promoters and promoter group shareholding						
	a. Pledged / encumbured						
	- No of Equity Shares	-	-	-	-	-	-
	- Percentage of Shares (of the shareholding of promoter and	-	-	-	-	-	-
	- Percentage of Shares (of the total share capital of the company)	-	-	-	-	-	-
	b. Non encumbured						
	- No of Equity Shares	51,99,400	51,99,400	51,99,400	51,99,400	51,99,400	51,99,400
	- Percentage of Shares (of the shareholding of promoter and	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.19%	64.19%	64.19%	64.19%

	Particulars	3 Months Ended (31/12/2019)
B.	Investor Complaints	-
	Pending at the beginning of the quarter	-
	Received during the quarter	-
	Disposed during the quarter	-
	Remaining unsolved during the quarter	-

TRIMURTHI LIMITED
Segment Reporting

	PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2019 (UNAUDITED)	30.09.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.03.2019 (AUDITED)
1.	**Segment Revenue**						
	a. Pharma Business	-	-		-	-	-
	b. Financial Services	10.80	8.21	14.13	31.89	44.94	57.64
	c. Investments	1.10	0.06	(0.23)	5.01	1.85	12.99
	d. Trading in Shares	18.34	14.73	3.56	52.20	20.83	30.81
	e. Foods	-	-	81.10	-	244.82	270.99
Total		**30.24**	**23.00**	**98.56**	**89.10**	**312.45**	**372.43**
Less: Inter Segment Revenue		-	-	-	-	-	-
Net Sales/ Income From Operations		**30.24**	**23.00**	**98.56**	**89.10**	**312.45**	**372.43**
2.	**Segment Profits (Before tax & Interest From Each Segment)**						
	a. Pharma Business	-	-	-	-	-	-
	b. Financial Services	10.80	15.05	11.85	31.89	36.68	45.45
	c. Investments	1.10	0.06	(0.23)	5.01	1.85	12.99
	d. Trading in Shares	(13.32)	(26.11)	2.44	(45.90)	9.16	13.97
	e. Foods	-	-	(13.67)	-	(42.82)	(53.33)
Total		**(1.42)**	**(11.00)**	**0.39**	**(9.00)**	**4.88**	**19.08**
Less:							
	i. Interest	-	-	-	-	-	-
	ii. Other Un-allocable expenses net off	-	-	-	-	-	-
	iii. Un-allocable Income	-	-	-	-	-	-
	Total Profit Before Tax	**(1.42)**	**(11.00)**	**0.40**	**(9.00)**	**4.88**	**19.08**
3.	**Capital Employed**						
	a. Pharma Business	29.50	-		29.50	-	-
	b. Financial Services	369.90	546.22	537.96	369.90	537.96	544.22
	c. Investments	30.19	259.88	268.24	30.19	268.24	272.16
	d. Trading in Shares	460.97	373.75	368.10	460.97	368.10	372.38
	e. Foods	300.00	12.34	12.15	300.00	12.15	12.29
	Total	**1,190.56**	**1,192.18**	**1,186.43**	**1,190.56**	**1,186.43**	**1,201.04**

Notes:

1 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.

2 The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 10-02-2020

3 The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34-Interim Financial Reporting prescribed under Section 133 of the Companies Act,2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.

Place : Hyderabad
Date : 10-02-2020

TRIMURTHI LIMITED ★ HYDERABAD ★
Arun Kumar

TRIMURTHI LIMITED
(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

Limited Review Report- Standalone Financial Results

To
The Board of Directors,
Trimurthi Limited,
Hyderabad.

Limited Review Report on unaudited standalone financial results for the Quarter and Nine Month ended 31th December 2019

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Trimurthi Limited** ("the Company") for the quarter ended 31th December 2019 and year to date results for the period 1stApril 2019 to 31th December 2019 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended , including relevant circulars issued by SEBI from time to time.

2. The preparation of "the Statement" in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India read with circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 10th February 2020. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

P. MURALI & CO., Hyderabad Chartered Accountants

P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants
FRN: 007257S

P. MURALI & CO. Hyderabad Chartered Accountants

M V JOSHI
Partner
M.No. 024784
UDIN: 20024784AAAABX5709

Place: Hyderabad
Date: 10-02-2020

TRIMURTHI LIMITED
SCHEDULE III OF THE COMPANIES ACT 2013
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS ENDED 31ST DECEMBER, 2019
PART-I

	Particulars	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2019 (UNAUDITED)	30.09.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.03.2018 (AUDITED)
I.	**Income From Operations**						
	Net Sales / Income from Operations	252.26	262.26	249.67	758.20	790.53	1,045.92
	Other Income	14.38	20.18	0.01	38.81	2.80	37.73
II.	**Total Income**	**266.64**	**282.44**	**249.67**	**797.01**	**793.33**	**1,083.65**
III.	**Expenses**						
	a. Consumption of Raw Material	154.05	35.59	39.70	221.11	125.39	154.21
	b. Purchase of Traded Goods/Shares	119.11	154.42	153.91	411.44	**447.57**	**594.28**
	c. (Increase)/Decrease in stock in trade and work in Progress	3.30	(0.18)	(18.44)	(6.55)	(17.28)	1.95
	d. Manufacturing Expenses	(45.92)	64.39	39.01	57.70	117.00	153.86
	e. Employee benefits expense	24.97	26.24	29.82	73.45	75.67	98.62
	f. Rent	1.50	1.50	2.20	4.50	5.85	7.80
	g. Finance Cost	3.01	2.67	2.93	9.38	9.61	12.97
	h. Depreciation	5.07	4.73	5.14	15.13	15.49	21.25
	i. Other Expenditure	11.50	10.78	10.02	36.86	40.75	51.12
	Total	**276.60**	**300.13**	**264.28**	**823.02**	**820.05**	**1,096.05**
IV.	**Profit/ (Loss) before Exceptional and Tax (II-III)**	**(9.95)**	**(17.69)**	**(14.61)**	**(26.02)**	**(26.72)**	**(12.40)**
V.	**Exceptional Items/Prior Period Items**	-	-		-		
VI.	**Profit/ (Loss) before tax (IV-V)**	**(9.95)**	**(17.69)**	**(14.61)**	**(26.02)**	**(26.72)**	**(12.40)**
VII.	**Tax expense:**	**0.86**	**(0.50)**	**(2.81)**	**3.01**	**(3.04)**	**2.38**
	(1) Current tax	0.65	(0.94)	1.29	1.86	5.42	10.51
	(2) Deferred tax	0.21	0.44	(4.09)	1.15	(8.46)	(8.12)
VIII	**Net Profit/ (Loss) for the period from continuing operations (VI-VII)**	**(10.81)**	**(17.19)**	**(11.80)**	**(29.03)**	**(23.68)**	**(14.79)**
IX.	**Profit/(loss) from discontinued operations**	-	-	-	-		-
X.	**Tax expenses of discontinued operations**	-	-	-	-		-
XI.	**Profit/(loss) from Discontinued operations (after tax) (IX-X)**	-	-	-	-		-
XII.	**Profit/(loss) for the period (VIII+XI)**	**(10.81)**	**(17.19)**	**(11.80)**	**(29.03)**	**(23.68)**	**(14.79)**
XIII.	**Other Comprehensive Income**						
	A. (i) Items that will not be reclassifled to proflt or loss	-	-	-			-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-			-
	B. (i) Items that will be reclassified to profit or loss	(0.19)	0.67	(2.30)	(1.42)	(10.18)	(0.43)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-			-
XIV.	**Total Comprehensive Income for the period (XII+XIII)Comprising Profit (Loss) and Other.comprehensive Income for the period)**	(11.00)	(16.52)	(14.10)	(30.45)	(33.86)	(15.21)
XV.	**Minority Interest**	0.92	0.10	0.71	2.15	5.49	9.40
XVI.	**Total Comprehensive Income for the period after Minority Interest (XIV-XV)**	**(11.93)**	**(16.63)**	**(14.81)**	**(32.60)**	**(39.35)**	**(24.62)**
XVII	**Earnings per equity share (for continuing operation):**						
	(1) Basic	**(0.14)**	**(0.21)**	**(0.15)**	**(0.38)**	**(0.36)**	**(0.30)**
	(2) Diluted	**(0.14)**	**(0.21)**	**(0.15)**	**(0.38)**	**(0.36)**	**(0.30)**
XVII	**Earnings per equity share (for discontinuing operation):**						
	(1) Basic	-	-	-	-	-	-
	(2) Diluted	-	-	-	-	-	-
XIX.	**Earnings per equity share (for discontinuing & continuing operation):**						
	(1) Basic	**(0.14)**	**(0.21)**	**(0.15)**	**(0.38)**	**(0.36)**	**(0.30)**
	(2) Diluted	**(0.14)**	**(0.21)**	**(0.15)**	**(0.38)**	**(0.36)**	**(0.30)**

TRIMURTHI LIMITED
(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED HYDERABAD
Arunkumar

TRIMURTHI LIMITED

SCHEDULE III OF THE COMPANIES ACT 2013

PART-II

	Particulars	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2019 (UNAUDITED)	30.09.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.03.2018 (AUDITED)
A.	**Particulars Of Share Holding**						
1.	Public Share Holding						
	- Number of Shares	29,00,600	29,00,600	29,00,600	29,00,600	29,00,600	29,00,600
	- Percentage of shareholding	35.81%	35.81%	35.81%	35.81%	35.81%	35.81%
2.	Promoters and promoter group shareholding						
	a. Pledged / encumbured						
	- No of Equity Shares	-	-	-	-	-	-
	- Percentage of Shares (of the shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of Shares (of the total share capital of the company)	-	-	-	-	-	-
	b. Non encumbured						
	- No of Equity Shares	51,99,400	51,99,400	51,99,400	51,99,400	51,99,400	51,99,400
	- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.19%	64.19%	64.19%	64.19%

	Particulars	3 Months Ended (31/12/2019)
B.	**Investor Complaints**	
	Pending at the beginning of the quarter	-NIL-
	Received during the quarter	-NIL-
	Disposed during the quarter	-NIL-
	Remaining unsolved during the quarter	-NIL-

Segment Reporting

	Particulars	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2019 (UNAUDITED)	30.09.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2019 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.03.2018 (AUDITED)
1.	**Segment Revenue**						
	a. Pharma Business	124.46	148.96	151.10	404.32	480.88	544.64
	b. Financial Services	13.08	7.39	14.13	33.35	44.94	76.96
	c. Investments	1.23	(0.07)	(0.23)	5.01	1.85	-
	d. Foods	109.46	111.09	81.11	301.71	244.82	259.71
	e. Trading in Shares	18.41	15.08	3.56	52.62	20.83	189.63
Total		**266.64**	**282.44**	**249.67**	**797.01**	**793.33**	**1,070.94**
Less: Inter Segment Revenue		-	-	-	-	-	-
Net Sales/ Income From Operations		**266.64**	**282.44**	**249.67**	**797.01**	**793.33**	**1,070.94**
2.	**Segment Profits (Before tax & Interest From Each Segment)**						
	a. Pharma Business	2.19	0.39	2.32	6.53	18.19	16.91
	b. Financial Services	13.08	14.09	8.92	33.35	27.07	54.40
	c. Investments	1.23	(0.07)	(0.23)	5.01	1.85	0.92
	d. Foods	(13.20)	(6.12)	(28.06)	(25.43)	(82.98)	(68.40)
	e. Trading in Shares	(13.25)	(25.97)	2.44	(45.48)	9.16	(8.58)
Total		**(9.95)**	**(17.69)**	**(14.61)**	**(26.02)**	**(26.72)**	**(4.75)**
Less:							
	i. Interest	-	-	-	-	-	16.01
	ii. Other Un-allocable expenses net off	-	-	-	-	-	-
	iii. Un-allocable Income	-	-	-	-	-	-
Total Profit Before Tax		**(9.95)**	**(17.69)**	**(14.61)**	**(26.02)**	**(26.72)**	**(20.76)**
3.	**Capital Employed**						
	a. Pharma Business	74.99	84.70	84.98	74.99	84.98	98.29
	b. Financial Services	369.90	449.46	450.93	369.90	450.93	521.58
	c. Investments	30.19	37.14	39.39	30.19	39.39	63.21
	d. Foods	123.41	189.09	189.71	123.41	189.71	219.43
	e. Trading in Shares	460.97	311.01	312.03	460.97	312.03	360.92
Total		**1,059.46**	**1,071.39**	**1,077.03**	**1,059.46**	**1,077.03**	**1,263.41**

TRIMURTHI LIMITED
(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED HYDERABAD

Arunkumar

TRIMURTHI
GROUP

Notes:

1 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.

2 The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 10-02-2020

3 The Consolidated Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs; Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III Division II of Companies Act, 2013. The Limited Review was carried out by Statutory Auditors for the Quarter ended 31st December 2019. The Ind AS Complaint figures for the Corresponding previous Quarter ended 30th September 2019 have not been subject to review or audit, however the Company's management has exercised necessary due deligence to ensure that such financial results provide a true and fair view of its affairs.

4 The results are also available on the webiste of the Company

Place : Hyderabad
Date : 10-02-2020

TRIMURTHI

Arun Kumar

TRIMURTHI LIMITED
(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

Limited Review Report – Consolidated Financial Results

To
The Board of Directors,
Trimurthi Limited,
Hyderabad.

Limited Review Report on unaudited consolidated financial results for the Quarter and Nine month ended 31th December 2019

1. We have reviewed the accompanying statement of unaudited consolidated financial results ("the statement") of Trimurthi Limited Group comprising Trimurthi Limited ("the Parent") and its subsidiaries (together referred to as 'the Group'), for the quarter ended 31th December 2019 and year to date results for the period 1stApril 2019 to 31th December 2019 ("the Statement")attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended , including relevant circulars issued by SEBI from time to time.

2. The preparation of "the Statement" in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 10th February 2020. Our responsibility is to express a conclusion on "the Statement" based on our review.

3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015as amended, to the extent applicable.

P. MURALI & CO., Hyderabad Chartered Accountants

P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

4. The consolidated unaudited results include the results of the following entities:

(a) Trimurthi Foods Limited (wholly owned subsidiary)

(b) Trimurthi Pharmaceuticals India Private Limited (subsidiary)

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali& Co.
Chartered Accountants
FRN: 007257S

P. MURALI & CO., Hyderabad, Chartered Accountants

M V JOSHI
Partner
M.No. 024784
UDIN: 20024784AAAABY6448

Place: Hyderabad
Date: 10-02-2020